

# HUEY LAW FIRM

---

zach@hueylawfirm.com (251) 270-4820

June 7, 2022

OTC Markets Group, Inc.  
300 Vesey Street, 12th Floor,  
New York, NY 10282

Re: Blue Diamond Ventures, Inc. (BLDV)  
Second Revised Attorney Letter for 2021 Fiscal Year  
as published by OTC Markets Group, Inc.

Ladies and Gentlemen:

Pursuant to the requirement established by OTC Markets Group, Inc. (“OTC”), I hereby confirm the following, specifically subject to the following limitations, exceptions, qualifications, and assumptions:

1. OTC is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933 (the “Act”).
2. The undersigned is a United States resident and has been retained by Issuer for the purpose of rendering this Letter and related matters. The undersigned has been retained as general counsel for the Issuer. The undersigned does not beneficially own any shares of the Issuer’s securities. The undersigned has not received, and has no agreement to receive in the future, shares of the Issuer’s stock in payment for services.
3. I have made such legal and factual examinations and inquiries as I have deemed advisable or necessary for the purpose of rendering this Letter. In addition, I have examined, among other things, originals or copies of such corporate records and documents of Issuer, certificates of public officials, and such other documents and questions of law that I considered necessary, advisable, or appropriate for the purpose of rendering this Letter.
4. The undersigned is a member of the Bar of the State of Colorado and the State of Alabama. I express no opinion as to the laws of any jurisdiction other than corporate laws of the State of Colorado; the State of Alabama; and the federal laws of the United States of America. I express no opinion with respect to the effect or application of any other laws, special rulings or authorities administering any such laws. Opinions or work of other counsel have not been sought or obtained by me in connection with rendering this letter.
5. The undersigned is permitted to practice before the Securities and Exchange Commission (the “SEC”) and has not been prohibited from practice thereunder. The undersigned is not, and has not within the past five years, been subject of an investigation, hearing, or proceeding by the SEC, U.S. Commodity Futures Trading Commission (“CFTC”), the Financial Industry Regulatory Authority (“FINRA”), or any other federal, state, or foreign regulatory agency.
6. The undersigned is not, and has not within the past five years, been suspended or barred from practicing in any state or jurisdiction. The undersigned has never been charged in a civil or criminal case.

7. In conducting my examination in connection with the delivery of this Letter, as to matters of fact I have relied upon information obtained from public officials, officers of Issuer, and other sources, and I confirm that I believed all such sources to be reliable. I further assumed without investigation (i) the genuineness of all signatures on original documents; (ii) the authenticity and completeness of all documents submitted to me as originals; (iii) the conformity to original documents of all documents submitted to me as copies; (iv) the legal capacity of all natural persons executing any documents; (v) the due authorization, execution, and delivery of all documents on all parties other than Issuer; and, (vi) the truth, accuracy and completeness of the information, factual matters, representations, and warranties contained in the information I received from public officials, officers of Issuer, and other sources.
8. In addition to the revised annual report for the most recently completed fiscal year and the annual report for prior completed fiscal year, the quarterly report for the first quarter of 2022 and the following documents have been reviewed by the undersigned in connection with the delivery of this Letter (the "Information"). The applicable date for this Letter is deemed to be December 31, 2021. Except in instances of confidentiality or for items and issues of a proprietary nature, the Information reviewed is publicly available through the OTC website with the date each respective document was posted on the OTC website noted below. This list does not include documents that are the subject of letters covering prior periods. The Information referenced includes as follows:

<b>PUBLISH DATE</b>	<b>TITLE</b>	<b>PERIOD END DATE</b>
06/06/2022	<u>Annual Report - Revised 2021 Annual Report BLDV</u>	12/31/2021
05/22/2022	<u>Annual Report - Revised Annual Report</u>	12/31/2021
05/15/2022	<u>Quarterly Report - BLDV 1st Quarter Financial Report</u>	03/31/2022
05/15/2022	<u>Quarterly Report - BLDV 1st Quarter Report</u>	03/31/2022
05/04/2022	<u>Annual Report - BLDV Annual report 2021</u>	12/31/2021
05/04/2022	<u>Annual Report - BLDV 2021 Financial Report</u>	12/31/2021
11/11/2021	<u>Quarterly Report - Quarterly Report BLDV - September 30th 2021</u>	09/30/2021
11/11/2021	<u>Quarterly Report - Financial Reports 3rd Quarter</u>	09/30/2021
10/28/2021	<u>Quarterly Report - Update for June 30th 2021 Report</u>	06/30/2021
09/27/2021	<u>Quarterly Report - 2nd Quarter Filing 2021</u>	06/30/2021
09/27/2021	<u>Quarterly Report - 2nd Quarter Report</u>	06/30/2021

<b>PUBLISH DATE</b>	<b>TITLE</b>	<b>PERIOD END DATE</b>
---------------------	--------------	------------------------

06/01/2021	<u>Quarterly Report - Updated 1st Quarter 2021 - May 31 2021</u>	03/31/2021
------------	------------------------------------------------------------------	------------

05/10/2021	<u>Quarterly Report - BLDV 1st Qtr Financials</u>	03/31/2021
------------	---------------------------------------------------	------------

And such other information and documents that I considered necessary under the specific circumstances to render this opinion.

9. The opinions and conclusions contained in this Letter are based upon the Information and facts made available to Counsel and are solely based on the accuracy of such Information and facts. In the event that the Information and facts are determined not to be true, this Letter is rescinded and to be deemed null and void.
10. To my knowledge, the Information, as of the date covered by Issuer's various disclosure and filings: (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); (iii) complies as to form with the OTC's Pink Basic Disclosure Guidelines; and (iv) has been posted through the OTC Disclosures & News Service.
11. The financial statements of the Issuer are not audited. Joshua Alper is responsible for and prepared the unaudited financial statements. Joshua Alper has 6 years' experience as CEO of the Issuer. Joshua Alper is the current CSO of the Issuer. The unaudited financial statements were prepared with the assistance of Kristi Kampmann, and Bodi Braithwaite of NOW CFO Denver V, LLC, 1801 Broadway Suite 537, Denver, Colorado. Ms. Kampmann has over 25 years' experience in accounting, audit, financial reporting & footnote creation, and paralegal support to OTC & SEC reporting companies. Mr. Braithwaite has over 10 years' experience in accounting, audit, and financial reporting support to OTC & SEC reporting companies. I have been advised that the financial statements were prepared in accordance with US GAAP.
12. The Issuer's transfer agent is Securities Transfer Corporation located at 2901 N Dallas Parkway Suite 380, Plano, Texas 75093. To my knowledge, Securities Transfer Corporation is registered with the SEC. In confirming the number of outstanding shares set forth in the Information, the undersigned relied upon data provided by the Issuer's transfer agent with respect to total shares issued as stated in the posted information described in Paragraph 8, above, the financial statements of the Issuer, and the corporate filings of the Issuer.
13. The undersigned hereby confirms that the undersigned has undertaken the following in connection with the delivery of this Letter: (i) met with management and a majority of the directors of the Issuer including Yale Peebles, CEO, Joshua Alper, CSO and Director, and Todd Scattini, Director; (ii) reviewed the Information, as amended, published by the Issuer through the OTC Disclosure & News Service; and (iii) discussed the Information with management and a majority of the directors of the Issuer.
14. To the best of my knowledge, after inquiry of management and the directors, neither the Issuer, any 5% shareholder, nor counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

15. No person other than the OTC is entitled to rely on this Letter. The OTC has full and complete permission and rights to publish the letter through the OTC Disclosure & News Service for public viewing.
16. Neither the Issuer, nor any of its predecessors, is or ever was a “shell company” as defined in Rules 405 of the Act and 12b-2 of the Exchange Act.

As used in this Letter, the expression “to my knowledge” or “to our knowledge” refers to the current actual knowledge of the undersigned (whether or not solely in connection with the delivery of this Letter or the preparation of the Information), and without any independent investigation of any underlying facts or situations. This Letter is expressly limited to the matter stated herein and no other opinions are implied by, or are to be inferred from, this Letter. Without limiting the prior sentence, I express no opinion as to any documents or matters except the Information as provided for herein and no opinion on any other matter may be inferred or implied from this Letter. This Letter is further limited to questions arising under the law of the State of Colorado and Alabama (where identified), and the federal laws of the United States of America (where identified). Accordingly, I express no opinion as to matters governed by the law of any other jurisdiction. This letter is based upon the law in effect on the date hereof, and I assume no obligation to revise or supplement it should such a law be changed by the legislative action, judicial decision, or otherwise. I further disclaim any obligation to update this Letter or to advise OTC or anyone else of facts, circumstances, events, or developments which hereafter may be brought to my attention and which may alter, affect, or modify this Letter.

On behalf of the Issuer, I appreciate your assistance. Please feel free to contact the undersigned should you have any comments or questions in regard to the information or any of the matters addressed herein.

Sincerely,



Zachary Huey, Esq.  
Huey Law Firm  
zach@hueylawfirm.com  
(251)270-4820